Tsunamasa Watanabe

Tsunamasa Watanabe

Auto-generated profile, based on publicly available information

Tsunamasa Watanabe

Division of Gastroenterology and Hepatology St. Marianna University School of Medicine Kawasaki Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
SKSahith Kudaravalli
Sahith Kudaravalli
DHDaniel Q Huang
Daniel Q Huang
MYMing-Lun Yeh
Ming-Lun Yeh
LTLindsey Trinh
Lindsey Trinh
PTP C Tsai
P C Tsai
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen

Verified
Journal Article
Open access
PDF file
RSRyuta Shigefuku
Ryuta Shigefuku
HTHideaki Takahashi
Hideaki Takahashi
HNHiroyasu Nakano
Hiroyasu Nakano
TWTsunamasa Watanabe
Tsunamasa Watanabe
KMKotaro Matsunaga
Kotaro Matsunaga
MSMichihiro Suzuki
Michihiro Suzuki
The progression of chronic liver disease differs by etiology. The aim of this study was to elucidate the difference in disease progression between chronic hepatitis C (CHC) and nonalcoholic fatty liver disease (NAFLD) by means of fibrosis markers, liver function, and hepatic tissue blood flow (TBF). Xenon computed tomography (Xe-CT) was performed in 139 patients with NAFLD and 152 patients with CHC (including liver cirrhosis (LC)). The cutoff values for fibrosis markers were compared between NAFLD and CHC, and correlations between hepatic TBF and liver function tests were examined at each fibrosis stage. The cutoff values for detection of the advanced fibrosis stage were lower in NAFLD than in CHC. Although portal venous TBF (PVTBF) correlated with liver function tests, PVTBF in initial LC caused by nonalcoholic steatohepatitis (NASH-LC) was significantly lower than that in hepatitis C virus (C-LC) (p = 0.014). Conversely, the liver function tests in NASH-LC were higher than those in C-LC (p < 0.05). It is important to recognize the difference between NAFLD and CHC. We concluded that changes in hepatic blood flow occurred during the earliest stage of hepatic fibrosis in patients with NAFLD; therefore, patients with NAFLD need to be followed carefully.


25 June 2025 in Hepatology
Verified
Journal Article
Closed access
JLJie Li
Jie Li
LXLiang Xu
Liang Xu
FRFajuan Rui
Fajuan Rui
STSally Tran
Sally Tran
Pei Chien TsaiPei Chien Tsai
Pei Chien Tsai
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
Background and Aims: Type 2 diabetes mellitus (T2DM), hepatic steatosis (HS), and chronic hepatitis B (CHB) frequently co-exist, but the association of T2DM with liver histology has not been well characterized. The study investigated the impact of T2DM on the presence and severity of liver fibrosis and inflammation in CHB patients with biopsy-proven HS (CHB-HS). Approach and Results: We enrolled CHB-HS patients who underwent liver biopsy from 19 medical centers (5 countries/regions) from 1990 to 2024. Propensity score matching (PSM) on age, sex, HBeAg, and HBV DNA levels was performed to balance background risks between CHB-HS patients with and without T2DM in a 1:3 ratio. The study included 1019 CHB-HS patients (mean age 40.3±10.4 years, 75.4% male, 10.5% T2DM). In the PSM cohort (106 T2DM, 320 non-T2DM), T2DM patients (vs. non-T2DM) had higher proportions with significant (stage ≥2) fibrosis (62.3% vs. 42.2%, p <0.01) but not with significant hepatic inflammation or moderate-to-severe steatosis (grade ≥2 for both). On multivariable logistic regression analyses, T2DM was an independent factor associated with significant fibrosis (aOR 1.86, 95% CI: 1.15–3.01, p =0.01), but not other components of metabolic syndrome. Meanwhile, HBeAg + and body mass index (BMI) rather than T2DM were associated with significant hepatic inflammation and moderate-to-severe steatosis, respectively, with similar findings in the total pre-PSM cohort. Conclusions: In CHB patients with concurrent HS, T2DM was an independent factor associated with significant fibrosis, HBeAg+ with hepatic inflammation, and BMI with moderate-to-severe steatosis, suggesting that both viral and metabolic control are crucial in the management of CHB patients with HS.

1 January 2022 in JGH Open
Verified
Journal Article
Open access
PDF file
TFTaito Fukushima
Taito Fukushima
MMManabu Morimoto
Manabu Morimoto
MUMakoto Ueno
Makoto Ueno
KKKousuke Kubota
Kousuke Kubota
HUHaruki Uojima
Haruki Uojima
SMShin Maeda
Shin Maeda
Aims: There is a paucity of comparative data on the use of sorafenib and lenvatinib for unresectable hepatocellular carcinoma. We assessed the real-world treatment outcomes between using sorafenib and lenvatinib for unresectable hepatocellular carcinoma in the multiple molecular-targeted therapy era. Methods and Results: We enrolled 386 patients treated with sorafenib or lenvatinib as the first-line therapy for unresectable hepatocellular carcinoma at multiple centers. Propensity score matching was performed to adjust for differences in baseline and tumor characteristics between the two groups. Propensity score matching identified 110 patients in each treatment group. The median overall survival was similar between lenvatinib and sorafenib (14.8 and 13.0 months, respectively; P = 0.352). The median progression-free survival was longer with lenvatinib than with sorafenib (7.6 and 3.9 months, respectively; P < 0.001). The overall response rate (P < 0.001) and disease control rate (P = 0.015), as defined by the modified Response Evaluation Criteria in Solid Tumors, were significantly better with lenvatinib than with sorafenib. The median overall survival was longer in patients who received subsequent treatment than in those who did not in the sorafenib group (23.1 and 5.7 months, respectively; P < 0.001), whereas the median overall survival with or without subsequent treatment did not differ significantly in the lenvatinib group (17.8 and 14.7 months, respectively; P = 0.439). Conclusion: Overall survival with sorafenib and lenvatinib was not significantly different. However, patients who received subsequent treatments had longer overall survival than those who received only first-line treatment with sorafenib, whereas lenvatinib did not show this effect.

1 November 2021 in JGH Open
Verified
Journal Article
Open access
PDF file
YSYosuke Satta
Yosuke Satta
RSRyuta Shigefuku
Ryuta Shigefuku
TWTsunamasa Watanabe
Tsunamasa Watanabe
TMTakuro Mizukami
Takuro Mizukami
TTTakashi Tsuda
Takashi Tsuda
FIFumio Itoh
Fumio Itoh
Background: Oxaliplatin is a key drug for the chemotherapy of colorectal cancer; however, it is also known to cause non-cirrhotic portal hypertension. We aimed to identify the characteristics of patients who developed esophagogastric varices (EGVs) after treatment with oxaliplatin. Methods: This study retrospectively analyzed patients with colorectal cancer who were treated with chemotherapy including oxaliplatin between 2010 and 2016. All patients were evaluated by contrast-enhanced computed tomography (CE-CT) every 3 months both during and after treatment; and endoscopy was performed when appearance of portal hypertension was suspected. Results: A total of 106 patients were divided into two groups: EGV formation (n = 6) and EGV non-formation (n = 100). In the EGV group, platelet counts decreased and the size of the spleen calculated by CT (CT spleen index; CT-SI) increased markedly. The highest area under the receiver operating characteristic curve (AUC) for the change in platelet counts was 0.81 (80% sensitivity and 83% specificity) at 3 months post treatment, and the maximum AUC for CT-SI was 0.89 (79% sensitivity and 83% specificity) at 6 months post treatment. Conclusions: EGV formation could be predicted by the assessment of platelet counts and spleen size. If progressive splenomegaly and thrombocytopenia are observed not only during but also after completion of the oxaliplatin-containing chemotherapy, EGVs should be confirmed by endoscopy for avoiding subsequent rupture.